Antibody–cytotoxic drug conjugates in clinical trials and future perspectives: the development of Trojan horses

ISSN： 1865-5041

Source： memo - Magazine of European Medical Oncology, Vol.7, Iss.1, 2014-02, pp. : 47-49

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Antibody–drug conjugates (ADCs)—new targeted therapies

By Papakonstantinou Georgios

memo - Magazine of European Medical Oncology, Vol. 6, Iss. 4, 2013-12 ,pp. : 223-224

Springer Publishing Company

Access to resources Recommend Favorite

Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins

Recent Patents on Anti-Cancer Drug Discovery, Vol. 9, Iss. 1, 2014-01 ,pp. : 35-65

Bentham Science Publishers

Access to resources Recommend Favorite

A Trojan Horse in Drug Development: Targeting of Thapsigargins Towards Prostate Cancer Cells

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 3, 2009-01 ,pp. : 276-294

Bentham Science Publishers

Access to resources Recommend Favorite

Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives

By Lassi Kiran Dawson Nancy A

Future Oncology, Vol. 7, Iss. 4, 2011-04 ,pp. : 551-558

Future Medicine

Access to resources Recommend Favorite

Advances in the Development of Site-Specific Antibody-Drug Conjugation

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 15, Iss. 7, 2015-01 ,pp. : 828-836

Bentham Science Publishers

Access to resources Recommend Favorite